Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Prostatic Adenocarcinoma: early-phase trial registry
1 of 2 indexed Prostatic Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Prostatic Adenocarcinoma: 2 US clinical trials tracked, 1 recruiting.
Prostatic Adenocarcinoma is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Rana McKay, MD, running 1 of these trials.
Enrollment posture brief
Registry condition prostatic-adenocarcinoma
OPEN 1 | RECR 50% | LATE 0 | EARLY 1 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Prostatic Adenocarcinoma lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Prostatic Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Prostatic Adenocarcinoma is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
Rana McKay, MD
NCT05498272
Androgen Deprivation Therapy Prior to Prostatectomy for Patients with Intermediate and High Risk Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT01542021
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Prostatic Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Prostatic Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Prostatic Adenocarcinoma page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Prostatic Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Rana McKay, MD sponsors the most Prostatic Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See Rana McKay, MD's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Prostatic Adenocarcinoma condition card totals 2 registered trials; most-linked intervention degarelix injection; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.